• Abera gets approval for Phase 1 trial of its Ab-01.12 intranasal pneumococcal vaccine

  The Dutch Central Committee on Research Involving Human Subjects has approved Abera Bioscience’s application for a Phase 1 clinical trial of its Ab-01.12 intranasal pneumococcal vaccine, the company said. According to Abera, the dose escalation… [Read more . . .]

• Kindeva hires Daniel Couto as Executive VP, Inhalation & Specialty Drug Delivery

  Drug delivery specialist CDMO Kindeva has announced the appointment of Daniel Couto as Executive VP, Inhalation & Specialty Drug Delivery. Couto was most recently COO at Vedanta Biosciences. His prior experience includes executive positions at Vedanta,… [Read more . . .]

• CHI’s Quattrii DPI selected for UCL inhaled biologics project

  Cambridge Healthcare Innovations announced that its Quattrii blister-based DPI has been selected for delivery of inhaled dry powder formulations of biologics being developed by University College London professor Jenny Lam. CHI partnered with Aptar in… [Read more . . .]

• 1nhaler raises additional £2.2 million for development of its single-dose salbutamol (albuterol) DPI

  1nhaler announced that it has closed a £2.2 million funding round led by Archangels, with the proceeds intended to support preparations for a clinical trial of its disposable, single-dose 1nhaler Salbutamol DPI with a goal… [Read more . . .]

• Tiziana says Phase 2a trial of intranasal foralumab in patients with na-SPMS met its primary endpoints

  Tiziana Life Sciences has announced that the Phase 2a INFORM-MS study of intranasal foralumab in patients with non-active secondary progressive multiple sclerosis met both of its primary endpoints, demonstrating significant reduction in microglial activation at Week… [Read more . . .]

• Merck initiates the Phase 3 ENHANCE-3 trial of Ohtuvarye ensifentrine inhalation suspension for the prevention of COPD exacerbations

• FDA clears IND for Phase 1 trial of United Therapeutics’ treprostinil / iloprost SMI

• Phase 2a trial of AerTherapeutics’ nebulized fexlamose failed to meet primary or secondary endpoints

• Blue Lake gets $5 million grant from the Gates Foundation for expansion of Phase 1/2a pediatric trial of intranasal vaccine against RSV

• DDL 2026 will feature the launch of a new incubator

More news . . .